This implies that the interaction between immune regulation and EGFR signaling may influence how the KIR–HLA profile predicts treatment outcomes in KRAS-WT metastatic colorectal cancer patients. This evidence concerns the gene KIR3DL1 and metastatic colorectal cancer.